Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
34.54
-2.75 (-7.37%)
At close: Sep 23, 2026, 4:00 PM EDT
34.54
0.00 (0.00%)
After-hours: Sep 23, 2026, 4:10 PM EDT
Immunovant Market Cap
Immunovant has a market cap or net worth of $7.13 billion as of September 23, 2026. Its market cap has increased by 162.52% in one year.
Market Cap
7.13B
Enterprise Value
6.34B
1-Year Change
162.52%
Ranking
Category
Stock Price
$34.54
ChartMarket Cap Chart
Since June 21, 2019, Immunovant's market cap has increased from $124.38M to $7.13B, an increase of 5,636.14%. That is a compound annual growth rate of 74.64%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 23, 2026 | 7.13B | 38.47% |
| Dec 31, 2025 | 5.15B | 41.70% |
| Dec 31, 2024 | 3.64B | -40.34% |
| Dec 29, 2023 | 6.09B | 165.79% |
| Dec 30, 2022 | 2.29B | 134.03% |
| Dec 31, 2021 | 979.80M | -78.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jun 21, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| ABIVAX Société Anonyme | 9.10B |
| ImmunityBio | 8.99B |
| Vaxcyte | 8.65B |
| Caris Life Sciences | 8.47B |
| Praxis Precision Medicines | 8.35B |
| TG Therapeutics | 8.07B |
| Spyre Therapeutics | 7.96B |
| Ionis Pharmaceuticals | 7.39B |